Advances in Particle Therapy for Cancer Treatment and Research
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 15 September 2024 | Viewed by 2300
Special Issue Editor
Special Issue Information
Dear Colleagues,
The dosimetric advantage afforded by high-energy particles, such as protons and Carbon ions, over conventional X-ray radiation has led to particle therapy being increasingly adopted for the treatment of many types of cancers. Clinical proton delivery technology is now mature enough that many standalone single-room proton centers can be reliably operated outside of major academic hospital facilities. This growth in the number of particle delivery centers came at a time of transition from passively scattered beams to a scanned pencil beam, which has further improved the dosimetric characteristics of particle therapy.
Recent advances in particle therapy have focused on reducing delivery uncertainties, such as development of in vivo imaging and adoption of dual-energy CT for stopping power calculation. To manage the effects of motion, 4D optimization and delivery techniques have been adopted. Plan optimization that incorporates radiobiological effects using parameters such as linear energy transfer is now feasible. On the treatment delivery front, proton arc therapy has been proposed as a method to optimize potential radiobiological effects while ultra-high-dose-rate delivery, also known as FLASH, is under active investigation for potential increased normal tissue dose-sparing effect. The field of artificial intelligence methods in radiotherapy is currently making rapid progress. Novel applications, such as dose prediction, quality assurance and plan optimization, will start to be applied towards particle therapy in the near future. As particle therapy becomes even more mature, some of these advances will become routine while others will fade only to have new ones emerge. This Special Issue will highlight some of these advances in the hope that they will eventually be adopted in particle therapy treatments of the future.
Dr. Boon-Keng Kevin Teo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- particle therapy
- FLASH
- LET
- adaptive therapy
- in vivo imaging
- adaptive therapy
- range verification
- robust optimization
